ANI Pharmaceuticals Appoints Henry Gosebruch to Board; Director Resigns

What Happened

• ANI Pharmaceuticals (ANIP) announced in an 8-K filed Aug 24, 2026 that the Board appointed Henry Gosebruch as a director on Aug 19, 2026. His term expires at the company’s 2027 annual meeting of stockholders.
• Mr. Gosebruch (age 53) currently serves as CEO of Lakefront Biotherapeutics (since May 2025) and previously was CEO of Neumora Therapeutics (Jul 2023–Feb 2025), Executive VP & Chief Strategy Officer at AbbVie (Dec 2015–Feb 2023), and spent 20+ years at J.P. Morgan including as Co‑Head of North American M&A.
• On Aug 23, 2026, Muthusamy “Samy” Shanmugam resigned from the Board effective immediately but will remain with ANI as Head of Research & Development and Chief Operating Officer of New Jersey Operations.

Key Details

• Appointment date: August 19, 2026; resignation effective: August 23, 2026.
• Term: Gosebruch’s board term expires at the 2027 annual meeting of stockholders.
• Compensation: As a non‑employee director, Gosebruch is eligible under ANI’s 2022 Stock Incentive Plan and will receive an initial restricted stock award with a grant‑date fair value of $525,000, vesting in three equal annual installments.
• No related arrangements or transactions involving Gosebruch were reported under Item 404(a) of Regulation S‑K.

Why It Matters

• This is a governance change investors should note: the board gains a director with significant pharmaceutical industry leadership and M&A experience, which could influence strategic oversight or deal activity.
• Management continuity in R&D and New Jersey operations is maintained because Mr. Shanmugam remains in his executive roles despite resigning from the board.
• Investors may want to monitor future ANI disclosures and press releases for any strategic initiatives or governance updates following this board change.